Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)

Daiichi Sankyo

Status and phase: Terminated; Phase 2

Conditions: Stroke

Treatments: Drug: piclozotan high dose; Drug: placebo; Drug: piclozotan low dose

Study type: Interventional

Funder types: Industry

Identifiers

NCT00272909

SPI-103

Details and patient eligibility

About

This research study is designed to evaluate the safety, tolerability, and efficacy of SUN N4057 (piclozotan) in subjects with acute ischemic stroke within 9 hours of the onset of symptoms.

Full description

The primary objective of the study is to determine the efficacy of a 72 hour infusion of SUN N4057 (piclozotan) in subjects with clinical findings of an acute ischemic stroke and a magnetic resonance imaging (MRI) demonstrating a measurable penumbra (perfusion-weighted imaging [PWI] minus diffusion-weighted imaging [DWI] volume). Efficacy will be determined by comparing the proportion of subjects with no growth in stroke lesion volume as assessed by DWI at Screening to stroke lesion volume assessed by FLAIR (fluid-attenuated inversion recovery) on Day 28 in the piclozotan group versus the placebo group.

Enrollment: 43 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

General inclusion criteria:

• Males or females >= 18 and <= 85 years of age at randomization. Female subjects must be either:

  • Surgically sterile;
  • Postmenopausal for at least 1 year; or
  • Non-pregnant, confirmed by a serum pregnancy test, and using a method of birth control that is acceptable to the investigator.

• Neurological examination demonstrating localizing cortical signs

• Receipt of study drug less than 6 hours (50% of subjects) or between 6 and 9 hours, inclusive, (50% of subjects) after the onset of symptoms (for un-witnessed stroke, last time seen in normal state or at bedtime for un-witnessed stroke during sleep)

• Signed informed consent from subject or legally acceptable representative

• NIHSS score of 6 - 22, inclusive, or at least 2 on the aphasia item of the NIHSS with a location of MRI findings consistent with aphasia

MRI-determined inclusion criteria:

• Acute ischemic stroke with substantial cortical involvement in the middle cerebral artery (MCA) distribution, as verified by the Screening DWI abnormality and/or Screening PWI abnormality. (Note: white matter involvement, in addition to cortex, is not an exclusion.)

Exclusion criteria

General exclusion criteria:

• Two or more of the following:

  • Reduced level of consciousness (score >= 2 on NIHSS Q1a)
  • Forced eye deviation or total gaze paresis (score of 2 on NIHSS Q2)
  • Dense hemiplegia (no movement) of upper and lower extremities (score of 4 on NIHSS Q5 regarding motor arm and a score of 4 on NIHSS Q6 regarding motor leg)

• Pre-stroke modified Rankin score >= 2 at Screening

• Rapid neurological improvement from Screening up to the start of drug infusion

• Persistent systolic blood pressure (SBP) > 220 mmHg and/or diastolic blood pressure (DBP) > 120 mmHg (confirmed by at least three readings taken at least 3 minutes apart) prior to randomization. If subsequent readings are consistently below these levels, either spontaneously or following mild antihypertensive therapy, subject may be enrolled.

MRI-determined exclusion criteria:

• Intracranial hemorrhage as verified by Screening MRI. (Note: intracranial hemorrhage on pre-screen computerized tomography [CT] scan also excludes subject.)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

43 participants in 3 patient groups, including a placebo group

1

Experimental group

Description:

piclozotan IV infusion, low dose, for 72 hours.

Treatment:

Drug: piclozotan low dose

2

Experimental group

Description:

piclozotan IV infusion, high dose, for 72 hours.

Treatment:

Drug: piclozotan high dose

3

Placebo Comparator group

Description:

placebo (normal saline) IV infusion, for 72 hours.

Treatment:

Drug: placebo